10-Q: Citius Pharma Reports Initial LYMPHIR Sales Amidst Going Concern Warning

Citius Pharmaceuticals reports its first commercial revenue from LYMPHIR, alongside a significant net loss and a 'going concern' warning, necessitating further capital raises.

Summary

• Citius Pharmaceuticals, Inc. reported its first commercial revenue of $3,944,111 from LYMPHIR sales for the three months ended December 31, 2025, with an approximate 80% gross profit margin.
• The company incurred a net loss of $9,393,889 for the quarter, a decrease from $10,281,246 in the prior year period.
• Net cash used in operating activities significantly increased to $13,008,822 for the quarter, compared to $4,725,852 in the same period last year.
• As of December 31, 2025, the company had cash and cash equivalents of $7,721,393 and a negative working capital of approximately $262,000.
• Management estimates available cash resources will fund operations only through May 2026, raising substantial doubt about the company's ability to continue as a going concern.
• Citius received a Nasdaq non-compliance notification on February 9, 2026, for failing to maintain a minimum bid price of $1.00, with a compliance period until August 10, 2026.
• The company's majority-owned subsidiary, Citius Oncology, is evaluating strategic alternatives and has retained Jefferies LLC as its financial advisor.
• Research and development expenses decreased by $527,319 to $1,599,719, primarily due to decreased costs for Mino-Lok following Phase 3 completion and pre-commercial manufacturing services for LYMPHIR.
• Stock-based compensation expense increased by $1,755,403 to $4,280,227, mainly due to Citius Oncology restricted stock awards granted in September 2025.
• Outstanding milestone payments include $18.25 million to Dr. Reddys for LYMPHIR approval (partially deferred) and approximately $6.8 million to Eisai for unpaid invoices (after the $5.9 million milestone was paid in full).
• Minimum purchase commitments for manufacturing and supply agreements total approximately $16.2 million for drug substance ($9.9M for 2025 prior obligations, $6.3M for 2026) and $4.0 million for finished drug products ($2.2M for 2026, $1.8M for 2027).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed but predominantly negative filing. While initial LYMPHIR revenue and positive Mino-Lok FDA guidance are encouraging, the explicit 'going concern' warning, significant cash burn, negative working capital, and Nasdaq non-compliance overshadow these positives, indicating severe financial distress.

Positives

• Generated first commercial revenue of $3,944,111 from LYMPHIR sales, indicating successful product launch.
• Achieved a strong gross profit margin of approximately 80% on LYMPHIR sales.
• Net loss decreased to $9,393,889 for the quarter, compared to $10,281,246 in the prior year period.
• FDA provided 'clear, constructive, and actionable guidance' for a future New Drug Application (NDA) submission for Mino-Lok, indicating a clear regulatory pathway.
• Successfully paid the $5.9 million milestone payment and accumulated interest to Eisai by December 15, 2025.

Negatives

• The company's independent registered public accounting firm's report includes an explanatory paragraph stating substantial doubt about its ability to continue as a going concern beyond May 2026.
• Experienced negative cash flows from operations of $13,008,822 for the three months ended December 31, 2025, a significant increase from $4,725,852 in the prior year.
• Reported a negative working capital of approximately $262,000 at December 31, 2025.
• Received a Nasdaq non-compliance notification on February 9, 2026, due to the common stock closing below $1.00 for 30 consecutive business days.
• An $18.25 million balance of a $27.5 million milestone payment remains due to Dr. Reddys for LYMPHIR approval.
• Owes approximately $6.8 million to Eisai for certain other unpaid invoices.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern.
• The company needs substantial additional funds and its ability to raise those funds is uncertain.
• There is a risk regarding the company's ability to regain compliance with Nasdaq's continued listing requirements.
• Uncertainty exists around Citius Oncology's ability to commercialize LYMPHIR, including covering licensing payments, manufacturing, and third-party costs.
• The anticipated benefits of the Citius Oncology reverse merger may not be fully realized or may take longer than expected.
• Risks are associated with obtaining regulatory approval for and successfully commercializing Mino-Lok.
• The cost, timing, and results of pre-clinical and clinical trials for other product candidates are uncertain.
• The company's ability to apply for, obtain, and maintain required regulatory approvals for its other product candidates is a risk.
• The estimated markets for LYMPHIR, Mino-Lok, or any future product candidates and their market acceptance are uncertain.
• Risks are present in the company's ability to obtain, perform under, and maintain financing and strategic agreements and relationships.
• The commercial feasibility and success of the company's technology and product candidates are not guaranteed.
• The company's ability to recruit and retain qualified management and technical personnel to carry out operations is a risk.

Future Outlook

The company expects to incur additional expenses as it continues to develop its product candidates, including seeking regulatory approval and protecting intellectual property. It anticipates that revenues will increase in the future as LYMPHIR gains market acceptance. However, the company will need to raise substantial additional capital to fund operations beyond May 2026 and cannot provide assurances that financing or strategic relationships will be available on acceptable terms or at all. Citius Oncology is actively evaluating strategic alternatives to maximize shareholder value.

Management Comments

• Management believes that revenues will increase in the future as LYMPHIR gains market acceptance.
• The FDA provided clear, constructive, and actionable guidance during the discussion, underscoring a pathway to support a future New Drug Application (NDA) submission for Mino-Lok.

Industry Context

StockSavvy.ai notes that Citius Pharmaceuticals operates in the highly capital-intensive biopharmaceutical industry, where late-stage development and commercialization of new drugs like LYMPHIR and Mino-Lok require significant and sustained funding. The initial revenue generation from LYMPHIR is a critical step, but the substantial net loss and 'going concern' warning highlight the inherent financial challenges faced by companies transitioning from R&D to commercialization, especially when multiple pipeline assets are in development. The Nasdaq non-compliance adds a layer of regulatory pressure common for smaller biotechs struggling with market valuation.

Comparison to Industry Standards

• The 80% gross profit margin for LYMPHIR is robust and generally favorable compared to many pharmaceutical products, indicating strong pricing power or efficient manufacturing costs for this specialized oncology immunotherapy.
• The 'going concern' warning is a significant red flag, placing Citius Pharmaceuticals below industry standards for financial stability, where established pharmaceutical companies typically demonstrate consistent profitability and positive operating cash flows.
• The need for continuous capital raises through equity offerings, as seen with Citius Pharma and Citius Oncology, is common for development-stage biotechs but contrasts with larger, cash-generating pharmaceutical firms like Pfizer or Johnson & Johnson, which fund R&D internally or through less dilutive means.
• The FDA's 'clear, constructive, and actionable guidance' for Mino-Lok's NDA submission is a positive signal, aligning with industry best practices for regulatory engagement, similar to how companies like Gilead Sciences or Amgen navigate complex drug approvals.

Corporate Governance

Related Party Transactions

• Leonard Mazur (Chairman and Chief Executive Officer) personally guaranteed repayment of a $1,000,000 note payable borrowed on June 2, 2025.
• Leonard Mazur purchased one share of Series A Preferred Stock for $100 on April 17, 2025, which carried 1,000,000,000 votes exclusively for the authorized share increase proposal, and was redeemed for $100 after the vote.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing and future equity raises, potential delisting from Nasdaq, and substantial uncertainty regarding the company's ability to continue as a going concern. However, initial LYMPHIR revenue and positive Mino-Lok FDA guidance offer some long-term potential.
• **Employees:** The 'going concern' warning could create uncertainty regarding job security, though the company continues to grant stock-based compensation.
• **Customers (Specialty Distributors/Healthcare Providers):** LYMPHIR's commercial launch provides a new product, but the company's financial instability could raise concerns about long-term supply reliability.
• **Suppliers/Creditors:** Dr. Reddys and Eisai are significant creditors with outstanding milestone payments and invoices. The partial deferral of Dr. Reddys' payment and the payment schedule for Eisai indicate active management of these obligations, but the overall financial health remains a concern.
• **Regulatory Authorities (FDA, Nasdaq):** The company is actively engaging with the FDA on Mino-Lok and is addressing Nasdaq's listing requirements, indicating compliance efforts.

Next Steps

• Raise additional capital to fund operations beyond May 2026.
• Regain compliance with Nasdaq's minimum bid price requirement by August 10, 2026.
• Citius Oncology to continue evaluating strategic alternatives with Jefferies LLC.
• Continue commercialization efforts for LYMPHIR to increase market acceptance and revenue.
• Pursue a New Drug Application (NDA) submission for Mino-Lok following FDA guidance.
• Continue development plans for Mino-Lok, Halo-Lido, and NoveCite.
• Initiate two investigator-initiated immuno-oncology trials and complete them by the four-year anniversary of the definitive agreement.

Key Dates

Recommendation

While the initial commercial revenue from LYMPHIR and the positive FDA guidance for Mino-Lok offer some long-term potential, the immediate and severe financial challenges, including the 'going concern' warning, negative working capital, significant cash burn, and Nasdaq non-compliance, create substantial risk. A 'hold' recommendation is appropriate for seasoned investors who are willing to monitor the company's progress on capital raising, commercialization, and regulatory milestones, acknowledging the high risk-reward profile. A 'sell' would be too aggressive given the new revenue stream and pipeline progress, but a 'buy' is unwarranted due to the significant liquidity concerns.

Keywords

Biopharmaceutical, Oncology, LYMPHIR, Mino-Lok, CTCL, Nasdaq compliance, Going concern, Clinical trials, Drug development, Capital raise, SEC filing, Biotech